vida: extract claims from 2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks

- Source: inbox/queue/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 5
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population.md

@@ -10,17 +10,17 @@ agent: vida
 sourced_from: health/2026-05-05-npr-glp1-eating-disorders-not-well-understood.md
 scope: structural
 sourcer: "NPR (@NPRHealth)"
-supports:
-- glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive
-- GLP-1 adolescent prescribing requires eating disorder screening because subclinical restrictive behaviors are clinically invisible without structured assessment
-related:
-- glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge
-- glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population
-- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
-reweave_edges:
-- GLP-1 adolescent prescribing requires eating disorder screening because subclinical restrictive behaviors are clinically invisible without structured assessment|supports|2026-05-07
+supports: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "GLP-1 adolescent prescribing requires eating disorder screening because subclinical restrictive behaviors are clinically invisible without structured assessment"]
+related: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population", "glp1-adolescent-prescribing-requires-eating-disorder-screening-because-subclinical-restriction-invisible-without-assessment", "glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification"]
+reweave_edges: ["GLP-1 adolescent prescribing requires eating disorder screening because subclinical restrictive behaviors are clinically invisible without structured assessment|supports|2026-05-07"]
 ---
 
 # GLP-1 prescribing creates systematic screening gap for atypical anorexia because normal BMI masks active restrictive psychopathology
 
 Dr. Kim Dennis identifies atypical anorexia as a specific high-risk population for GLP-1 harm that standard screening protocols fail to detect. Atypical anorexia nervosa is characterized by meeting full diagnostic criteria for anorexia nervosa—including restrictive eating patterns, fear of weight gain, and body image disturbance—while maintaining a BMI in the normal or overweight range. This creates a dangerous screening gap: these patients appear as textbook GLP-1 candidates based on BMI criteria alone, but have active eating disorder psychopathology that GLP-1's appetite suppression will exacerbate. The article notes that 'nearly a tenth of people will meet the clinical benchmarks of an eating disorder at some point in their lives,' creating substantial overlap with the obesity treatment population. Dr. Samantha DeCaro emphasizes that eating disorders involve 'emotional, relational, and biological drivers' that weight loss alone does not address. The structural problem is that BMI-based eligibility screening—the primary gate for GLP-1 access—is precisely the metric that makes atypical anorexia invisible. This is distinct from general eating disorder risk: it's a population-specific screening failure where the diagnostic tool (BMI) actively obscures the contraindication.
+
+## Extending Evidence
+
+**Source:** NPR Health, Feb 2026, clinical expert interviews
+
+Clinicians identify atypical anorexics as 'at high risk of being harmed' because they 'restrict food but maintain normal weight' making the condition invisible to doctors. Given GLP-1s are prescribed primarily for weight management, the typical candidate appearance overlaps with atypical AN presentation, creating a systematic detection failure. Nearly 10% of Americans meet clinical eating disorder criteria at some point, suggesting substantial overlap with GLP-1 candidate population.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -117,3 +117,9 @@ Systematic review explicitly states 'caution is warranted in individuals with an
 **Source:** Sa et al. (2026)
 
 Review recommends 'monthly check-ins with validated depression/suicidality tools' and 'psychoeducation for patients and caregivers' but provides no operational guidance on eating disorder screening despite acknowledging the risk. This confirms the gap is structural infrastructure, not clinical knowledge.
+
+## Supporting Evidence
+
+**Source:** NPR Health, Feb 2026, interviews with Robyn Pashby (psychologist) and Samantha DeCaro (clinician)
+
+NPR reporting confirms that 'most patients receive NO evaluation for eating disorders before GLP-1 prescription' and that drugs are 'easy to obtain online, with little screening.' Psychologist Robyn Pashby notes the screening gap exists despite identified risk populations. This provides journalistic confirmation of the structural screening gap documented in clinical literature.

domains/health/glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-05-05-timmermanreport-dark-side-glp1-eating-disorders.
 scope: structural
 sourcer: Luke Timmerman (Timmerman Report)
 supports: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
-related: ["SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
+related: ["SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population", "glp1-adolescent-prescribing-requires-eating-disorder-screening-because-subclinical-restriction-invisible-without-assessment", "glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification"]
 ---
 
 # GLP-1 eating disorder screening lacks reimbursement infrastructure despite identified risk population
@@ -24,3 +24,10 @@ Despite evidence of elevated eating disorder risk in GLP-1 users with prior ment
 **Source:** NPR investigation, curator analysis
 
 Article implicitly confirms reimbursement gap by noting that screening is not occurring despite identified at-risk populations. The curator notes connect this to 'value-based care transitions stall at the payment boundary'—screening costs are not reimbursed, creating the same structural barrier that blocks SDOH intervention.
+
+
+## Supporting Evidence
+
+**Source:** NPR Health, Feb 2026
+
+Source confirms 'no national guidelines requiring ED screening before prescription — only recommended by some professional groups' and notes screening is recommended but not practiced. This parallels the SDOH Z-code pattern where screening produces better outcomes but no reimbursement exists for the time required.

domains/health/glp1-harm-mediated-by-cultural-weight-stigma-not-pharmacology-alone.md

@@ -10,17 +10,17 @@ agent: vida
 sourced_from: health/2026-05-05-npr-glp1-eating-disorders-not-well-understood.md
 scope: causal
 sourcer: "NPR (@NPRHealth)"
-supports:
-- glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway
-related:
-- glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap
-- glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway
-- glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive
-- glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations
-- glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge
-- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
+supports: ["glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
+related: ["glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-harm-mediated-by-cultural-weight-stigma-not-pharmacology-alone", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population"]
 ---
 
 # GLP-1 harm risk is mediated by cultural weight stigma and pressure rather than pharmacological properties alone
 
 Robyn Pashby articulates the dual-truth framework: 'GLP-1s are legitimate evidence-based treatments for obesity, but they also sit inside our culture, which has intense weight pressure, weight stigma and eating disorder risk.' This positions harm not as inherent to the drug but as emergent from the interaction between pharmacological appetite suppression and a cultural environment that valorizes thinness and stigmatizes weight. Dr. DeCaro emphasizes that GLP-1s are 'potentially more harmful' than prior weight-loss drugs because they 'make it harder for people to nourish themselves regularly, or tune into their natural hunger cues'—but this harm manifests specifically in individuals with 'emotional, relational, and biological drivers' that predispose to eating disorders. The article identifies at-risk groups as 'those with prior body-weight trauma/bullying, atypical anorexia, genetic predisposition to reduced satiety, men with eating disorders (underdiagnosed), people obtaining online without clinical evaluation.' This is a fundamentally different causal model than direct pharmacological induction: the drug creates vulnerability that cultural context converts into harm. The mechanism is cultural amplification of pharmacological effect, not pharmacological determinism. This explains why the same drug produces different outcomes in different populations and why behavioral/psychological factors are 'primary determinants of who is harmed.'
+
+
+## Supporting Evidence
+
+**Source:** NPR Health, Feb 2026
+
+Psychologist Robyn Pashby frames the issue as holding 'two truths: That GLP-1s are legitimate evidence-based treatments for obesity, but that they also sit inside our culture, which has intense weight pressure, weight stigma and eating disorder risk.' Clinician Samantha DeCaro notes weight loss alone rarely addresses 'emotional, relational, and biological drivers' of eating disorders. This confirms the cultural context amplifies pharmacological risk.

inbox/archive/health/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md

@@ -7,10 +7,13 @@ date: 2026-02-04
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-08
 priority: high
 tags: [glp1, eating-disorders, anorexia, atypical-anorexia, screening-gaps, access, misuse]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content